Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data (Q30653245)

25 June 2017

title

Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data (English)

1 reference

25 June 2017

Willan AR

1

1 reference

25 June 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Contemporary Clinical Trials

25 June 2017

published in

1 reference

25 June 2017

volume

22

1 reference

25 June 2017

issue

3

1 reference

25 June 2017

page(s)

228-237

1 reference

In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Costs, effects and C/E-ratios alongside a clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Confidence intervals for cost/effectiveness ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Carrier screening for cystic fibrosis: costs and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

On the (near) equivalence of cost-effectiveness and cost-benefit analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

The interpretation of results of economic evaluation: explicating the value of health

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

A note on confidence intervals in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Incremental net benefit in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Sample size calculation in economic evaluations

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

An economic approach to clinical trial design and research priority-setting

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Handling uncertainty in economic evaluations of healthcare interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

A Bayesian approach to stochastic cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

Bayesian cost-effectiveness analysis from clinical trial data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900110-6

7 January 2021

10.1016/S0197-2456(01)00110-6

Identifiers

DOI

1 reference

25 June 2017

1 reference